帕米磷酸二钠治疗骨纤维结构不良的观察
DOI:
作者:
作者单位:

1.山东中医药大学第一临床医学院;2.解放军联勤保障部队第九六〇医院骨科

作者简介:

通讯作者:

中图分类号:

基金项目:


Observation of pamidronate in the treatment of fibrous dysplasia
Author:
Affiliation:

1.The first clinical medical college, Shandong University of traditional Chinese Medicine, Jinan;2.Department of Orthopedics, the 960th Hospital of the PLA Joint Logistics Support Force

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘要:[目的]探讨帕米磷酸二钠治疗骨纤维结构不良的临床疗效。[方法]回顾性分析2011年1月至2021年1月我科收治的38例骨纤维结构不良患者。治疗方式均为静脉滴注帕米磷酸二钠。[结果]与用药前相比,用药6个月和末次随访时患者VAS评分明显降低(P<0.05),SF-36评分显著提高(P<0.05),血清I型胶原C端肽、血清I型胶原氨基端前肽显著降低(P<0.05),但是血清骨钙素差异无统计学意义(P>0.05)。在用药后六个月后,3例患者出现病变区域再填充或缩小,32例患者病变区域未发生变化,3例患者的病变区域出现增大。在末次随访时,7例患者出现病变区域再填充或缩小,27例患者病变区域未发生变化,4例患者的病变区域出现增大。1例患者首次用药时出现短暂性发热,5例患者用药期间出现病理性骨折。[结论]帕米磷酸二钠治疗骨纤维结构不良具有一定的临床疗效,能够减轻患者疼痛,降低骨代谢指标,延缓疾病的进展,并且不良反应轻微。

    Abstract:

    Abstract: [Objective] To investigate the clinical efficacy of pamidronate in the treatment of fibrous dysplasia. [Methods] 38 patients with fibrous dysplasia treated in the Department of orthopaedics of the 960th Hospital of the PLA Joint Logistics Support Force from January 2011 to January 2021 were analyzed retrospectively. The treatment methods were intravenous pamidronate disodium. [Results] Compared with before treatment, the VAS score of patients decreased significantly P<0.05) and SF-36 score increased significantly (P<0.05) at 6 months after treatment and the last follow-up. In terms of bone metabolism indexes, C1NP and PINP decreased significantly (P<0.001), but the difference of OST was not statistically significant (P>0.05). After six months of treatment, the lesion area was refilled or reduced in 3 patients, unchanged in 32 patients and enlarged in 3 patients. At the last follow-up, the lesion area was refilled or reduced in 7 patients, unchanged in 27 patients and enlarged in 4 patients. One patient had transient fever when taking the medicine for the first time, and five patients had pathological fractures during taking the medicine. [Conclusion] Pamidronate disodium has a certain clinical effect in the treatment of bone fibrous dysplasia.It can reduce the pain and bone metabolism of patients and delay the progress of the disease.And it has few adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2022-01-14
  • 最后修改日期:2022-04-05
  • 录用日期:2022-08-16
  • 在线发布日期:
  • 出版日期: